Bright Minds Biosciences Inc Asset Resilience Ratio
Bright Minds Biosciences Inc asset resilience ratio. Bright Minds Biosciences Inc (DRUG) has an Asset Resilience Ratio of 0.06% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Bright Minds Biosciences Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Bright Minds Biosciences Inc (2021–2025)
Asset resilience ratio of Bright Minds Biosciences Inc from 2021 to 2025. This chart shows how Bright Minds Biosciences Inc's Asset Resilience Ratio has changed over time. Read Bright Minds Biosciences Inc debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Bright Minds Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Bright Minds Biosciences Inc (DRUG) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $172.78K | 0.06% |
| Total Liquid Assets | $172.78K | 0.06% |
Asset Resilience Insights
- Limited Liquidity: Bright Minds Biosciences Inc maintains only 0.06% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Bright Minds Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Bright Minds Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 15.21% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Immunovant Inc
NASDAQ:IMVT |
Biotechnology | 98.50% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Amicus Therapeutics Inc
NASDAQ:FOLD |
Biotechnology | 8.37% |
Bright Minds Biosciences Inc Asset Resilience Ratio by Year (2021–2025)
Bright Minds Biosciences Inc asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for Bright Minds Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-09-30 | 0.07% | $61.93K | $84.42 Million | -1.18pp |
| 2023-09-30 | 1.25% | $86.25K | $6.88 Million | +0.54pp |
| 2022-09-30 | 0.71% | $86.25K | $12.09 Million | +0.28pp |
| 2021-09-30 | 0.43% | $86.25K | $20.04 Million | -- |
About Bright Minds Biosciences Inc
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials… Read more